HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jennifer R Grandis Selected Research

Squamous Cell Carcinoma of Head and Neck

1/2022NSAIDs Overcome PIK3CA Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models.
11/2021Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.
11/2021PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance.
10/2021Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer.
10/2021Treatment of Fanconi Anemia-Associated Head and Neck Cancer: Opportunities to Improve Outcomes.
1/2021Caspase-8 mutations associated with head and neck cancer differentially retain functional properties related to TRAIL-induced apoptosis and cytokine induction.
1/2021Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
11/2020Head and neck squamous cell carcinoma.
6/2020Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer.
1/2020STAT3 decoy oligonucleotide-carrying microbubbles with pulsed ultrasound for enhanced therapeutic effect in head and neck tumors.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jennifer R Grandis Research Topics

Disease

139Neoplasms (Cancer)
01/2022 - 06/2003
123Squamous Cell Carcinoma of Head and Neck
01/2022 - 10/2003
63Head and Neck Neoplasms (Head and Neck Cancer)
01/2022 - 09/2005
15Carcinogenesis
01/2020 - 03/2005
7Neoplasm Metastasis (Metastasis)
01/2018 - 08/2005
7Lung Neoplasms (Lung Cancer)
05/2015 - 09/2006
5Carcinoma (Carcinomatosis)
01/2017 - 11/2004
4Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2020 - 01/2014
4Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
02/2013 - 02/2005
3Papillomavirus Infections
11/2018 - 10/2014
3Hypoxia (Hypoxemia)
01/2017 - 11/2009
3Mouth Neoplasms (Oral Cancer)
08/2016 - 07/2010
3Lymphatic Metastasis
01/2016 - 09/2006
3Glioblastoma (Glioblastoma Multiforme)
09/2014 - 09/2006
3Squamous Cell Neoplasms (Squamous Cell Cancer)
01/2013 - 06/2008
2Colorectal Neoplasms (Colorectal Cancer)
01/2020 - 12/2015
2Triple Negative Breast Neoplasms
02/2019 - 01/2016
2Disease Progression
01/2017 - 10/2014

Drug/Important Bio-Agent (IBA)

63ErbB Receptors (EGF Receptor)IBA
01/2022 - 06/2003
43Cetuximab (Erbitux)FDA Link
11/2021 - 09/2006
31Proteins (Proteins, Gene)FDA Link
11/2021 - 10/2007
25Biomarkers (Surrogate Marker)IBA
10/2021 - 03/2005
15Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2017 - 07/2007
14Tyrosine Kinase InhibitorsIBA
11/2021 - 06/2003
14Monoclonal AntibodiesIBA
11/2020 - 06/2003
13Phosphotransferases (Kinase)IBA
01/2020 - 11/2004
11STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA
10/2019 - 03/2008
11DNA (Deoxyribonucleic Acid)IBA
10/2018 - 07/2010
11Biological ProductsIBA
11/2015 - 08/2005
10Cisplatin (Platino)FDA LinkGeneric
11/2021 - 09/2006
8Messenger RNA (mRNA)IBA
10/2021 - 06/2008
8Pharmaceutical PreparationsIBA
10/2021 - 06/2007
7Small Interfering RNA (siRNA)IBA
05/2021 - 06/2008
7Interleukin-6 (Interleukin 6)IBA
01/2020 - 10/2011
7OligonucleotidesIBA
01/2020 - 05/2009
7LigandsIBA
12/2019 - 06/2006
6Tyrosine (L-Tyrosine)FDA Link
01/2019 - 06/2007
5Immune Checkpoint InhibitorsIBA
10/2021 - 09/2016
5Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
05/2021 - 06/2005
5RNA (Ribonucleic Acid)IBA
02/2021 - 10/2014
5CytokinesIBA
01/2021 - 03/2005
5NucleotidesIBA
01/2020 - 02/2013
5Transcription Factors (Transcription Factor)IBA
01/2020 - 08/2012
5src-Family KinasesIBA
01/2017 - 07/2008
5Gefitinib (Iressa)FDA Link
07/2011 - 02/2005
4Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
10/2021 - 09/2004
4EnzymesIBA
01/2021 - 03/2013
4Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
06/2020 - 06/2009
4Janus KinasesIBA
01/2020 - 06/2005
4Dasatinib (BMS 354825)FDA Link
01/2017 - 05/2012
4epidermal growth factor receptor VIIIIBA
01/2015 - 09/2006
4Cyclin D1IBA
01/2015 - 04/2005
4Epidermal Growth Factor (EGF)IBA
04/2014 - 07/2008
4Cyclooxygenase 2 (Cyclooxygenase-2)IBA
03/2013 - 09/2004
3Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA
01/2022 - 01/2019
3Caspase 8 (Caspase-8)IBA
01/2021 - 10/2014
3Mechanistic Target of Rapamycin Complex 1IBA
02/2019 - 11/2012
3Oncogene Proteins (Oncogene Protein)IBA
01/2018 - 10/2014
3AntibodiesIBA
09/2016 - 05/2012
3CarcinogensIBA
08/2016 - 04/2005
3Protein Tyrosine PhosphatasesIBA
05/2016 - 01/2014
3Annexin A5IBA
02/2014 - 10/2007
3Indicators and Reagents (Reagents)IBA
01/2014 - 02/2011
3G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
01/2014 - 01/2008
3Bombesin Receptors (Bombesin Receptor)IBA
02/2013 - 03/2008
3Proteasome InhibitorsIBA
12/2012 - 06/2008
3Bortezomib (Velcade)FDA Link
12/2012 - 06/2008
2AlpelisibIBA
11/2021 - 01/2019
2Protein Kinases (Protein Kinase)IBA
10/2021 - 11/2018
2Protein Isoforms (Isoforms)IBA
10/2021 - 05/2021
2Lysine (L-Lysine)FDA Link
01/2021 - 06/2008
2Doxycycline (Periostat)FDA LinkGeneric
01/2021 - 11/2018
2sulforaphaneIBA
12/2019 - 07/2016
2Tumor Biomarkers (Tumor Markers)IBA
10/2019 - 01/2018
2matrigelIBA
11/2018 - 07/2008
2Gastrin-Releasing PeptideIBA
11/2018 - 02/2009
2Antisense DNAIBA
10/2018 - 03/2009
2Antineoplastic Agents (Antineoplastics)IBA
01/2018 - 04/2014
2Interleukin-6 Receptors (Interleukin 6 Receptor)IBA
01/2018 - 01/2014
2Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2018 - 06/2017
2tyrosine receptor (receptor, tyrosine)IBA
01/2018 - 06/2008
2Mitogen-Activated Protein KinasesIBA
01/2017 - 09/2012
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2017 - 12/2008
2TOR Serine-Threonine KinasesIBA
12/2016 - 11/2012
24-Nitroquinoline-1-oxide (4 Nitroquinoline 1 oxide)IBA
07/2016 - 02/2011
2MicroRNAs (MicroRNA)IBA
01/2016 - 11/2015
2Sulindac (Copal)FDA LinkGeneric
06/2014 - 11/2012
2Celecoxib (Celebrex)FDA Link
03/2014 - 03/2013
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
12/2013 - 10/2011

Therapy/Procedure

58Therapeutics
10/2021 - 06/2003
13Radiotherapy
10/2021 - 06/2003
13Drug Therapy (Chemotherapy)
11/2020 - 06/2003
5Chemoprevention
12/2019 - 02/2011
4Immunotherapy
01/2021 - 11/2009
4Chemoradiotherapy
11/2020 - 02/2009
3Precision Medicine
01/2020 - 01/2016
2Microbubbles
01/2020 - 01/2015
2Aftercare (After-Treatment)
01/2017 - 01/2015
2Oral Administration
03/2015 - 10/2012
2Molecular Targeted Therapy
04/2014 - 01/2013